Associated tags: Transfusion medicine, Hematology, Health, Infection, Quality of life, Neurology, GRF, Grifols, Research, News
Locations: NORTH AMERICA, EUROPE, SPARTA, AUSTRALIA, SOUTH SAN FRANCISCO, CA, US, IV, SC, BARCELONA, ES, SPAIN, UNITED STATES, EGYPT, CANADA, NORTH CAROLINA, CLAYTON, FLORIDA, UNITED STATES OF AMERICA
GBI,
Miles Laboratories,
Green Building Initiative,
Biodiversity,
Certification,
Laboratory,
Cutter Laboratories,
Infection,
Health,
Research Triangle Park,
EUR,
Research,
Growth,
History,
Engineering,
Therapy,
Antibody,
LEED,
Patient,
UL (safety organization),
Acquisition,
Robotics,
GOLD,
MCE,
GRF,
Quality of life,
COVID-19,
Pharmaceutical industry Fifty years ago, the site opened as Cutter Laboratories and produced modest quantities of a single medicine, albumin, distributed domestically.
Key Points:
- Fifty years ago, the site opened as Cutter Laboratories and produced modest quantities of a single medicine, albumin, distributed domestically.
- Its present plasma processing capacity of 12 million liters annually is more than half of the company’s current global capability.
- Acquiring the site from Talecris Biotherapeutics in 2011 turned Grifols into a top-three plasma-sector powerhouse.
- Innovations at Clayton are being replicated today at new Grifols manufacturing sites in Montreal, Canada, and Cairo, Egypt.
GRFS,
International,
Sustainability,
Annual report,
Class,
American depositary receipt,
MD,
EUR,
Risk management,
International Financial Reporting Standards,
Bank statement,
MCE,
GRF,
Growth Grifols' annual report on Form 20-F provides investors with an overview of the company's governance practices, including information about the Board of Directors and its committees, executive compensation, and risk management.
Key Points:
- Grifols' annual report on Form 20-F provides investors with an overview of the company's governance practices, including information about the Board of Directors and its committees, executive compensation, and risk management.
- Grifols' ordinary shares (Class A) are listed on the Spanish stock market and form part of the IBEX-35 (GRF).
- Grifols will deliver, within a reasonable time after request, a hard copy of the annual report on Form 20-F, including its complete audited financial statements, free of charge, to any shareholder upon request.
- To request a hard copy, shareholders may contact Grifols by email at [email protected] to the attention of Grifols' Investor Relations & Sustainability, Re: 2023 Annual Report on Form 20-F.
Certification,
Plasma,
CE,
GRFS,
Risk,
Arbovirus,
Climate,
RNA,
GRF,
Fever Dream,
IVDR,
Chikungunya,
Death,
Dengue virus,
MCE,
Blood bank,
NAT,
Vertically transmitted infection,
Medical device These are the four most significant arboviruses of concern, all spread through mosquito vectors.
Key Points:
- These are the four most significant arboviruses of concern, all spread through mosquito vectors.
- With the dengue virus alone, there were more than 5 million cases and 5,000 deaths reported globally in 2023.1
Further strengthening the Grifols Procleix portfolio for blood donor screening, the Procleix ArboPlex Assay uses plasma or serum samples to detect arboviral RNA.
- Blood banks and collection centers could decide that deferrals are unnecessary if donors were tested and found negative using the Procleix ArboPlex Assay.
- “With its 4-in-1 arbovirus test feature, the Grifols Procleix ArboPlex Assay has the ability to speed up and overall improve donor screening laboratory efficiency,” said Antonio Martínez, president of Grifols Diagnostic Business Unit.
NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Grifols S.A. (“Grifols” or the “Company”) (NASDAQ: GRFS).
Key Points:
- NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Grifols S.A. (“Grifols” or the “Company”) (NASDAQ: GRFS).
- The investigation concerns whether Grifols and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- On this news, Grifol’s ADR price fell $0.46 per ADR, or 6.94%, to close at $6.17 per ADR on March 5, 2024.
- Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
SAN FRANCISCO, March 29, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges investors in Grifols, S.A. (NASDAQ: GRFS – ADR ADR Class B) who suffered substantial losses to submit your losses now .
Key Points:
- SAN FRANCISCO, March 29, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges investors in Grifols, S.A. (NASDAQ: GRFS – ADR ADR Class B) who suffered substantial losses to submit your losses now .
- Grifols S.A. (GRFS – ADR ADR Class B) Investigation:
Shares in embattled Spanish pharmaceutical and chemical manufacturer Grifols S.A. declined sharply again on Mar.
- Gotham’s latest report takes issue with Grifols’ disclosure of a 319 million euro ($346.6 million) loan in its 2022 Annual Report.
- 5, 2024, securities analysts at Alantra Equities downgraded Grifols shares, reporting saying it had “lost confidence” in the company.
POMPANO BEACH, Fla., April 8, 2024 /PRNewswire/ -- International Medical Industries, Inc. (IMI) is thrilled to announce an innovative partnership with Grifols that promises to enhance medication safety through cutting-edge technology.
Key Points:
- POMPANO BEACH, Fla., April 8, 2024 /PRNewswire/ -- International Medical Industries, Inc. (IMI) is thrilled to announce an innovative partnership with Grifols that promises to enhance medication safety through cutting-edge technology.
- IMI, the industry leader in secure drug delivery devices, is joining forces with Kiro Grifols, dedicated to the state-of-the-art automated pharmacy compounding device (PCD), KIRO Fill.
- Their commitment to quality and patient safety perfectly aligns with Kiro Grifols' mission to deliver innovative solutions that enhance pharmacy automation and accuracy.
- This strategic partnership aims to reshape the landscape of pharmaceutical compounding, setting a new benchmark for safety, precision, and reliability.
Research,
Communication,
FY,
GRFS,
SAN,
Person,
Disclosure,
American depositary receipt,
Annual report,
Hagens Berman,
Life insurance SAN FRANCISCO, March 25, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges investors in Grifols, S.A. (NASDAQ: GRFS – ADR ADR Class B) who suffered substantial losses to submit your losses now .
Key Points:
- SAN FRANCISCO, March 25, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges investors in Grifols, S.A. (NASDAQ: GRFS – ADR ADR Class B) who suffered substantial losses to submit your losses now .
- Grifols S.A. (GRFS – ADR ADR Class B) Investigation:
Shares in embattled Spanish pharmaceutical and chemical manufacturer Grifols S.A. declined sharply again on Mar.
- Gotham’s latest report takes issue with Grifols’ disclosure of a 319 million euro ($346.6 million) loan in its 2022 Annual Report.
- 5, 2024, securities analysts at Alantra Equities downgraded Grifols shares, reporting saying it had “lost confidence” in the company.
NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Grifols S.A. (“Grifols” or the “Company”) (NASDAQ: GRFS).
Key Points:
- NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Grifols S.A. (“Grifols” or the “Company”) (NASDAQ: GRFS).
- The investigation concerns whether Grifols and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- On this news, Grifol’s ADR price fell $0.46 per ADR, or 6.94%, to close at $6.17 per ADR on March 5, 2024.
- Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
SAN DIEGO, March 22, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating Grifols, S.A. (NASDAQ: GRFS) (OTC: GIKLY, GIFOF, GIFLF) or potential securities law violations.
Key Points:
- SAN DIEGO, March 22, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating Grifols, S.A. (NASDAQ: GRFS) (OTC: GIKLY, GIFOF, GIFLF) or potential securities law violations.
- For more details on the investigation, visit
What is Johnson Fistel investigating?
- The investigation pertains to whether executives at the company misrepresented or failed to timely disclose material and adverse information to investors.
- Individuals with nonpublic information regarding the company should consider whether to assist our investigation or take advantage of the SEC Whistleblower program.
Retrieved on:
Wednesday, March 20, 2024
Research,
Communication,
FY,
GRFS,
SAN,
Person,
Disclosure,
American depositary receipt,
Annual report,
Hagens Berman,
Cryptocurrency SAN FRANCISCO, March 20, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges investors in Grifols, S.A. (NASDAQ: GRFS – ADR ADR Class B) who suffered substantial losses to submit your losses now .
Key Points:
- SAN FRANCISCO, March 20, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges investors in Grifols, S.A. (NASDAQ: GRFS – ADR ADR Class B) who suffered substantial losses to submit your losses now .
- Grifols S.A. (GRFS – ADR ADR Class B) Investigation:
Shares in embattled Spanish pharmaceutical and chemical manufacturer Grifols S.A. declined sharply again on Mar.
- Gotham’s latest report takes issue with Grifols’ disclosure of a 319 million euro ($346.6 million) loan in its 2022 Annual Report.
- 5, 2024, securities analysts at Alantra Equities downgraded Grifols shares, reporting saying it had “lost confidence” in the company.
